Conference Reports for NATAP

Conference on Retroviruses and Opportunistic Infections Seattle, Washington Feb 19-22 2023 Back

Tweet

CROI 2023: LA CAB/RPV Treatment, CAB Prevention Updates, New Data       CROI: Cabotegravir Pharmacology in the Background of Delayed Injections in HPTN 084 - (02/22/23)   CROI: CABOTEGRAVIR FOR HIV PrEP IN US BLACK MEN AND TRANSGENDER WOMEN WHO HAVE SEX WITH MEN - (02/23/23) HPTN 083   CROI: The LEVI Syndrome: Characteristics of early HIV infection with cabotegravir for PrEP - (02/23/23) HPTN 083 and HPTN 084   CROI: CAB LA FOR HIV PREVENTION IN AFRICAN CISGENDER FEMALE ADOLESCENTS (HPTN 084-01) - (02/23/23)   CROI: Long-Acting CAB for PrEP Acceptable, Safe in Adolescent Female Africans - i- (02/25/23)   CROI: Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With HIV-1 - (02/23/23)   CROI: HIGH VIROLOGIC SUPPRESSION RATES ON LONG-ACTING ART IN A SAFETY-NET CLINIC POPULATION - (02/23/23)   CROI: Projected Benefits of Long-Acting ART (LA-ART) in PWH Viremic Not Taking Oral Therapy - (02/23/23)   CROI: SOLAR (Switch Onto Long-Acting Regimen) 12-Month Results - Randomized Switch Trial of CAB + RPV LA vs. Oral BIC/FTC/TAF - (02/23/23)   CROI: FAVORABLE METABOLIC OUTCOMES 48 WEEKS AFTER SWITCH TO DTG/3TC - (02/24/23)   CROI: Weight and Metabolic Changes With Cabotegravir + Rilpivirine Long-Acting or Bictegravir/Emtricitabine/Tenofovir Alafenamide - (02/23/23)   NATAP CROI coverage... Conference on Retroviruses and Opportunistic Infections Seattle, Washington Feb 19-22 2023